<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32632925</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1539-6924</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Risk analysis : an official publication of the Society for Risk Analysis</Title><ISOAbbreviation>Risk Anal</ISOAbbreviation></Journal><ArticleTitle>Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.</ArticleTitle><Pagination><StartPage>320</StartPage><EndPage>328</EndPage><MedlinePgn>320-328</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/risa.13555</ELocationID><Abstract><AbstractText>After the globally coordinated cessation of any serotype of oral poliovirus vaccine (OPV), some risks remain from undetected, existing homotypic OPV-related transmission and/or restarting transmission due to several possible reintroduction risks. The Global Polio Eradication Initiative (GPEI) coordinated global cessation of serotype 2-containing OPV (OPV2) in 2016. Following OPV2 cessation, the GPEI and countries implemented activities to withdraw all the remaining trivalent OPV, which contains all three poliovirus serotypes (i.e., 1, 2, and 3), from the supply chain and replace it with bivalent OPV (containing only serotypes 1 and 3). However, as of early 2020, monovalent OPV2 use for outbreak response continues in many countries. In addition, outbreaks observed in 2019 demonstrated evidence of different types of risks than previously modeled. We briefly review the 2019 epidemiological experience with serotype 2 live poliovirus outbreaks and propose a new risk for unexpected OPV introduction for inclusion in global modeling of OPV cessation. Using an updated model of global poliovirus transmission and OPV evolution with and without consideration of this new risk, we explore the implications of the current global situation with respect to the likely need to restart preventive use of OPV2 in OPV-using countries. Simulation results without this new risk suggest OPV2 restart will likely need to occur (81% of 100 iterations) to manage the polio endgame based on the GPEI performance to date with existing vaccine tools, and with the new risk of unexpected OPV introduction the expected OPV2 restart probability increases to 89%. Contingency planning requires new OPV2 bulk production, including genetically stabilized OPV2 strains.</AbstractText><CopyrightInformation>&#xa9; 2019 Society for Risk Analysis. This article has been contributed to by US Government employees and their work is in the public domain in the USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kalkowska</LastName><ForeName>Dominika A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallansch</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-1015-4818</Identifier><AffiliationInfo><Affiliation>National Center for Immunization and Respiratory, Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cochi</LastName><ForeName>Stephen L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Stephanie D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wassilak</LastName><ForeName>Steven G F</ForeName><Initials>SGF</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Kimberly M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0002-0849-9147</Identifier><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U2R GH001913</GrantID><Acronym>GH</Acronym><Agency>CGH CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Risk Anal</MedlineTA><NlmUniqueID>8109978</NlmUniqueID><ISSNLinking>0272-4332</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015438" MajorTopicYN="N">Health Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012308" MajorTopicYN="N">Risk Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dynamic modeling</Keyword><Keyword MajorTopicYN="N">oral poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">polio eradication</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32632925</ArticleId><ArticleId IdType="mid">NIHMS1661529</ArticleId><ArticleId IdType="pmc">PMC7814395</ArticleId><ArticleId IdType="doi">10.1111/risa.13555</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blake IM, Pons-Salort M, Molodecky NA, Diop OM, Chenoweth P, Bandyopadhyay AS, &#x2026; Grassly NC (2018). Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine. N Engl J Med, 379(9), 834&#x2013;845. doi:10.1056/NEJMoa1716677</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1716677</ArticleId><ArticleId IdType="pmc">PMC5985919</ArticleId><ArticleId IdType="pubmed">30157398</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. (2001). Circulation of a type 2 vaccine-derived poliovirus--Egypt, 1982&#x2013;1993. MMWR Morb Mortal Wkly Rep, 50(3), 41&#x2013;42, 51. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=11215882</Citation><ArticleIdList><ArticleId IdType="pubmed">11215882</ArticleId></ArticleIdList></Reference><Reference><Citation>Diop OM, Asghar H, Gavrilin E, Moeletsi NG, Benito GR, Paladin F, &#x2026; Quddus A (2017). Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 - Worldwide, 2016&#x2013;2017. Morbidity and Mortality Weekly Report, 66(20), 538&#x2013;542. doi:10.15585/mmwr.mm6620a4</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6620a4</ArticleId><ArticleId IdType="pmc">PMC5657872</ArticleId><ArticleId IdType="pubmed">28542124</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, &amp; Thompson KM (2016a). Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of inadvertent trivalent oral poliovirus vaccine use. BMC Infectious Diseases, 16, 231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888482</ArticleId><ArticleId IdType="pubmed">27246198</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, &amp; Thompson KM (2016b). Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of potential non-synchronous cessation. BMC Infectious Diseases, 16, 237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888482</ArticleId><ArticleId IdType="pubmed">27246198</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, &amp; Thompson KM (2018). Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use. BMC Infect Dis, 18(1), 165. doi:10.1186/s12879-018-3074-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-018-3074-0</ArticleId><ArticleId IdType="pmc">PMC5892013</ArticleId><ArticleId IdType="pubmed">29631539</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, &amp; Thompson KM (2016). Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. Journal of Vaccines and Vaccination, 7(5), 340. doi:10.4172/2157-7560.1000340</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2157-7560.1000340</ArticleId><ArticleId IdType="pmc">PMC5497833</ArticleId><ArticleId IdType="pubmed">28690915</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Kalkowska DA, &amp; Thompson KM (2018). Poliovirus containment risks and their management. Future Virology, 13(9), 617&#x2013;628. doi:10.2217/fvl-2018-0079</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl-2018-0079</ArticleId><ArticleId IdType="pmc">PMC7885305</ArticleId><ArticleId IdType="pubmed">33598044</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Kalkowska DA, &amp; Thompson KM (2019). Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission. BMJ Open, 9(1), e023938. doi:10.1136/bmjopen-2018-023938</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-023938</ArticleId><ArticleId IdType="pmc">PMC6340450</ArticleId><ArticleId IdType="pubmed">30647038</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Alexander JP, &amp; Thompson KM (2010). Optimal vaccine stockpile design for an eradicated disease: Application to polio. Vaccine, 28(26), 4312&#x2013;4327.</Citation><ArticleIdList><ArticleId IdType="pubmed">20430122</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kew OM, C&#xe1;ceres VM, Jafari H, Cochi SL, &#x2026; Thompson KM (2006). Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Analysis, 26(6), 1471&#x2013;1505.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184393</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kim J-H, Burns CC, Kew OM, Oberste MS, &#x2026; Thompson KM (2013). Review: Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Analysis, 23(4), 680&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7890645</ArticleId><ArticleId IdType="pubmed">23470192</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Wassalik SGF, Cochi SL, &amp; Thompson KM (2015). An economic analysis of poliovirus risk management policy options for 2013&#x2013;2052. BMC Infectious Diseases, 15(389), doi:10.1186/s12879-12015-11112-12878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-12015-11112-12878</ArticleId><ArticleId IdType="pmc">PMC4582932</ArticleId><ArticleId IdType="pubmed">26404632</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL, &amp; Thompson KM (2016). Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infectious Diseases, 16, 137. doi:10.1186/s12879-016-1465-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-016-1465-7</ArticleId><ArticleId IdType="pmc">PMC4806487</ArticleId><ArticleId IdType="pubmed">27009272</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, &amp; Thompson KM (2017). Poliovirus vaccination during the endgame: Insights from integrated modeling. Expert Review of Vaccines, 16(6), 577&#x2013;586. doi:10.1080/14760584.2017.1322514</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2017.1322514</ArticleId><ArticleId IdType="pubmed">28437234</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, &amp; Thompson KM (2018). Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Review of Vaccines, 17(8), 739&#x2013;751. doi:10.1080/14760584.2018.1506333</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1506333</ArticleId><ArticleId IdType="pmc">PMC6168953</ArticleId><ArticleId IdType="pubmed">30056767</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. (2015, September
20, 2015). Global eradication of wild poliovirus type 2 declared. Retrieved from http://www.polioeradication.org/mediaroom/newsstories/Global-eradication-of-wild-poliovirus-type-2-declared/tabid/526/news/1289/Default.aspx</Citation></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SGF, &#x2026; Thompson KM (2015). Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. Journal of Infectious Diseases, 211(11), 1800&#x2013;1812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887763</ArticleId><ArticleId IdType="pubmed">25505296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, &amp; Thompson KM (2020). Insights from modeling preventive supplemental immunization activities as a strategy to eliminate wild poliovirus transmission in Pakistan and Afghanistan. Risk Analysis, doi: 10.1111/risa.13471. doi:10.1111/risa.13471</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13471</ArticleId><ArticleId IdType="pmc">PMC7821345</ArticleId><ArticleId IdType="pubmed">32144841</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Wassilak SGF, Cochi SL, Pallansch MA, &amp; Thompson KM (2020). Global transmission of live polioviruses: Updated integrated dynamic modeling of the polio endgame. Risk Analysis, doi: 10.1111/risa.13447. doi:10.1111/risa.13447</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13447</ArticleId><ArticleId IdType="pmc">PMC7787008</ArticleId><ArticleId IdType="pubmed">31960533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Morris-Glasgow V, Landaverde M, Burns C, Shaw J, Garib Z, &#x2026; de Quadros C (2002). Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science, 296(5566), 356&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">11896235</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroiss SJ, Famulare M, Lyons H, McCarthy KA, Mercer LD, &amp; Chabot-Couture G (2017). Evaluating cessation of the type 2 oral polio vaccine by modeling pre- and post-cessation detection rates. Vaccine, 35(42), 5674&#x2013;5681. doi:10.1016/j.vaccine.2017.08.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.08.048</ArticleId><ArticleId IdType="pubmed">28890193</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, O&#x2019;Reilly KM, Grassly NC, Edmunds. J, Mach O, Gopala S, &#x2026; Sutter RW (2020). Evolving epidemiology of poliovirus serotype 2 following withdrawal of the type 2 oral 1 poliovirus vaccine. Science, In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt LR, Estivariz CF, &amp; Sutter RW (2014). Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. Journal of Infectious Diseases, 210(Suppl 1), S380&#x2013;389. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25316859</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10424844</ArticleId><ArticleId IdType="pubmed">25316859</ArticleId></ArticleIdList></Reference><Reference><Citation>Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. (2017). World population prospects. The 2017 revision. . Retrieved from https://esa.un.org/unpd/wpp/</Citation></Reference><Reference><Citation>PTI. (2018). Samples of oral polio vaccine found adulterated: MoS Health. Retrieved from https://www.newindianexpress.com/nation/2018/dec/13/samples-of-oral-polio-vaccine-found-adulterated-mos-health-1910936.html</Citation></Reference><Reference><Citation>Thompson KM, &amp; Duintjer Tebbens RJ (2008). The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation. The Medscape Journal of Medicine, 10(8), 190
Retrieved from http://journal.medscape.com/viewarticle/578396</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562150</ArticleId><ArticleId IdType="pubmed">18924642</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, &amp; Duintjer Tebbens RJ (2012). Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. Expert Review of Vaccines, 11(4), 449&#x2013;459. doi:10.1586/erv.11.195</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.11.195</ArticleId><ArticleId IdType="pubmed">22551030</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, &amp; Duintjer Tebbens RJ (2017). Lessons from globally-coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. Journal of Infectious Diseases, 216(Suppl 1), S168&#x2013;S175. doi:10.1093/infdis/jix128</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix128</ArticleId><ArticleId IdType="pmc">PMC5853947</ArticleId><ArticleId IdType="pubmed">28838198</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, &amp; Kalkowska DA (2019). Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). Expert Review of Vaccines, 18(7), 725&#x2013;736. doi:10.1080/14760584.2019.1635463</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2019.1635463</ArticleId><ArticleId IdType="pmc">PMC6816497</ArticleId><ArticleId IdType="pubmed">31248293</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, &amp; Kalkowska DA (2020). Reflections on modeling poliovirus transmission and the polio eradication endgame. Risk Analysis, 10.1111/risa.13484. doi:10.1111/risa.13484</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13484</ArticleId><ArticleId IdType="pmc">PMC7983882</ArticleId><ArticleId IdType="pubmed">32339327</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, &amp; Duintjer Tebbens RJ (2015). Managing population immunity to reduce or eliminate the risks of circulation following the importation of live polioviruses Vaccine, 33(3), 1568&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7907970</ArticleId><ArticleId IdType="pubmed">25701673</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, &amp; Cochi SL (2013). Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Analysis, 33(4), 647&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896539</ArticleId><ArticleId IdType="pubmed">22985171</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, De Coster I, Bandyopadhyay AS, Revets H, Withanage K, De Smedt P, &#x2026; Gast C (2019). The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet, 394(10193), 148&#x2013;158. doi:10.1016/s0140-6736(19)31279-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(19)31279-6</ArticleId><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>World Bank. (2019). World Bank analytical classifications - calendar year 2017 GNI per capita in US$ (Atlas methodology). Retrieved from http://databank.worldbank.org/data/download/site-content/OGHIST.xls</Citation></Reference><Reference><Citation>World Health Assembly. (1988). Global eradication of poliomyelitis by the year 2000 (resolution 41.28). Retrieved from http://www.who.int/csr/ihr/polioresolution4128en.pdf</Citation></Reference><Reference><Citation>World Health Assembly. (2008). Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1). Retrieved from http://apps.who.int/gb/ebwha/pdf_files/WHA61-REC1/A61_Rec1-part2-en.pdf</Citation></Reference><Reference><Citation>World Health Organization. (2019). World schedule as of 2018/July/11. Retrieved from http://apps.who.int/immunization_monitoring/globalsummary/schedules</Citation></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. (2019). Polio eradication and endgame strategic plan (2019&#x2013;2023). Geneva; 2019. Report No: WHO/POLIO/19.04. Retrieved from http://polioeradication.org/wp-content/uploads/2019/05/polio-endgame-strategy-2019-2023.pdf</Citation></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. (2020a). Circulating vaccine-derived poliovirus. Retrieved from http://polioeradication.org/wp-content/uploads/2020/06/weekly-polio-analyses-cVDPV-20200616.pdf</Citation></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. (2020b). Strategy for the response to type 2 circulating vaccine-derived poliovirus 2020&#x2013;2021: Addendum to the Polio eradication and endgame strategic plan (2019&#x2013;2023). Geneva; 2020. Report No: WHO/POLIO/20.02. Retrieved from http://polioeradication.org/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>